article thumbnail

TAE Life Sciences Welcomes Dr. Deepak “Dee” Khuntia to Its Board of Directors

Pharma Mirror

As an authority in radiation oncology, Dr. Khuntia joining the board of directors validates BNCT and the work TAE Life Sciences is doing to make it a mainstay of modern cancer care IRVINE, Calif.- FASTRO, to its esteemed Board of Directors.

article thumbnail

Podcast #1: Doing Digital Deals in Life Sciences | Corporate Culture

Pharmaceutical Technology

The first episode in Sterling's podcast series on digital dealmaking in life sciences puts a spotlight on corporate culture

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Digital dilemma in UK’s life sciences job market

Pharmaceutical Technology

In this issue: Digital jobs in UK life sciences, generative AI changes drug discovery, and how robotics is impacting gene therapy manufacturing.

article thumbnail

Wave Life Sciences gets grant for improved method for synthesizing phosphoramidites with higher yields and purities

Pharmaceutical Technology

Wave Life Sciences Ltd patent reveals a groundbreaking method for synthesizing high-purity oligonucleotides with increased yields. Learn more about this innovative process now!

article thumbnail

Navigating the 2024 Life Science Industry Trends Landscape

Pharma Mirror

As we step into 2024, the global life science industry finds itself at a crossroads, facing plenty of challenges alongside an abundance of exciting opportunities. The pharmaceutical and contract outsourcing space has shifted, with new trends emerging that will shape the future of this rapidly changing industry.

article thumbnail

How life sciences benefits from broader healthcare transformation

Bio Pharma Dive

Digital transformation has much to offer life sciences as well as healthcare — and the synergies between the two can further optimize the power of digital health, clinical trials and patient outcomes.

article thumbnail

Forbion raises $1.47bn for two life sciences-focused funds

Pharmaceutical Technology

European life sciences venture capital firm Forbion has raised €1.35bn ($1.47bn) across its two new funds. The Forbion Growth Opportunities Fund II provides support to the expansion of late-stage life sciences companies. The latest fundraising brings the total funds managed by the company to €3bn ($3.28bn).